The A1/A2 ß-casein genotype of cows, but not their horn status, influences peptide generation during simulated digestion of milk.

The effect of the horn status of cows on their milk composition and quality is a controversial research topic. In this study, 128 milk samples from 64 horned and 64 disbudded Brown Swiss and Original Braunvieh cows were collected from alpine farms where both horned and disbudded cows were grazing on mountain pastures. The samples were analyzed for their detailed composition and protein digestion in a simulated in vitro digestion (INFOGEST). To exclude probable influences on digestion, the ß-casein genotype with its variants A1 and A2 was also included in the study. The effects of horn status and ß-casein genotype were investigated in linear mixed models, which included additional influencing random factors such as Original Braunvieh blood proportion, stage of lactation, and farm. Horn status did not have any effect on milk composition or digestion. In contrast, milk from A1A1 cows showed a different protein digestion than milk of A1A2 and A2A2 cows in the gastric phase, including smaller amounts of ß-casomorphin(BCM)21-associated peptides and larger amounts of BCM11-associated peptides. Abundances of BCM7 did not differ between ß-casein genotypes. At the end of the intestinal phase, the digested milk of A1A1 and A2A2 b-casein genotypes did not differ.

Anthropogenic aerosol drives uncertainty in future climate mitigation efforts.

The 2016 Paris agreement set a global mean surface temperature (GMST) goal of not more than 2 degrees Celsius above preindustrial. This is an ambitious goal that will require substantial decreases in emission rates of long-lived greenhouse gasses (GHG). This work provides a mathematical framework, based on current state of the art climate models, to calculate the GHG emissions consistent with prescribed GMST pathways that meet the Paris agreement goal. The unique capability of this framework, to start from a GMST timeseries and efficiently calculate the emissions required to meet that temperature pathway, makes it a powerful resource for policymakers. Our results indicate that aerosol emissions play a large role in determining the near-term allowable greenhouse gas emissions that will limit future warming to 2 °C, however in the long term, drastic GHG emissions reductions are required under any reasonable aerosol scenario. With large future aerosol emissions, similar to present day amounts, GHG emissions need to be reduced 8% by 2040 and 74% by 2100 to limit warming to 2 °C. Under a more likely low aerosol scenario, GHG emissions need to be reduced 36% and 80% by 2040 and 2100, respectively. The Paris agreement Intended Nationally Determined Contributions are insufficient to meet this goal.

Efficacy of Climate Forcings in PDRMIP Models.

Quantifying the efficacy of different climate forcings is important for understanding the real-world climate sensitivity. This study presents a systematic multimodel analysis of different climate driver efficacies using simulations from the Precipitation Driver and Response Model Intercomparison Project (PDRMIP). Efficacies calculated from instantaneous radiative forcing deviate considerably from unity across forcing agents and models. Effective radiative forcing (ERF) is a better predictor of global mean near-surface air temperature (GSAT) change. Efficacies are closest to one when ERF is computed using fixed sea surface temperature experiments and adjusted for land surface temperature changes using radiative kernels. Multimodel mean efficacies based on ERF are close to one for global perturbations of methane, sulfate, black carbon, and insolation, but there is notable intermodel spread. We do not find robust evidence that the geographic location of sulfate aerosol affects its efficacy. GSAT is found to respond more slowly to aerosol forcing than CO2 in the early stages of simulations. Despite these differences, we find that there is no evidence for an efficacy effect on historical GSAT trend estimates based on simulations with an impulse response model, nor on the resulting estimates of climate sensitivity derived from the historical period. However, the considerable intermodel spread in the computed efficacies means that we cannot rule out an efficacy-induced bias of ±0.4 K in equilibrium climate sensitivity to CO2 doubling when estimated using the historical GSAT trend.

Correlation between in vitro and in vivo data on food digestion. What can we predict with static in vitro digestion models?

During the last decade, there has been a growing interest in understanding food's digestive fate in order to strengthen the possible effects of food on human health. Ideally, food digestion should be studied in vivo on humans but this is not always ethically and financially possible. Therefore, simple in vitro digestion models mimicking the gastrointestinal tract have been proposed as alternatives to in vivo experiments. Thus, it is no surprise that these models are increasingly used by the scientific community, although their various limitations to fully mirror the complexity of the digestive tract. Therefore, the objective of this article was to call upon the collective experiences of scientists involved in Infogest (an international network on food digestion) to review and reflect on the applications of in vitro digestion models, the parameters assessed in such studies and the physiological relevance of the data generated when compared to in vivo data. The authors provide a comprehensive review in vitro and in vivo digestion studies investigating the digestion of macronutrients (i.e., proteins, lipids, and carbohydrates) as well as studies of the bioaccessibility and bioavailability of micronutrients and phytochemicals. The main conclusion is that evidences show that despite the simplicity of in vitro models they are often very useful in predicting outcomes of the digestion in vivo. However, this has relies on the complexity of in vitro models and their tuning toward answering specific questions related to human digestion physiology, which leaves a vast room for future studies and improvements.

Transport of ice into the stratosphere and the humidification of the stratosphere over the 21st century.

Climate models predict that tropical lower-stratospheric humidity will increase as the climate warms. We examine this trend in two state-of-the-art chemistry-climate models. Under high greenhouse gas emissions scenarios, the stratospheric entry value of water vapor increases by ~1 part per million by volume (ppmv) over this century in both models. We show with trajectory runs driven by model meteorological fields that the warming tropical tropopause layer (TTL) explains 50-80% of this increase. The remainder is a consequence of trends in evaporation of ice convectively lofted into the TTL and lower stratosphere. Our results further show that, within the models we examined, ice lofting is primarily important on long time scales - on interannual time scales, TTL temperature variations explain most of the variations in lower stratospheric humidity. Assessing the ability of models to realistically represent ice-lofting processes should be a high priority in the modeling community.

Stratospheric ozone depletion due to nitrous oxide: influences of other gases.

The effects of anthropogenic emissions of nitrous oxide (N(2)O), carbon dioxide (CO(2)), methane (CH(4)) and the halocarbons on stratospheric ozone (O(3)) over the twentieth and twenty-first centuries are isolated using a chemical model of the stratosphere. The future evolution of ozone will depend on each of these gases, with N(2)O and CO(2) probably playing the dominant roles as halocarbons return towards pre-industrial levels. There are nonlinear interactions between these gases that preclude unambiguously separating their effect on ozone. For example, the CH(4) increase during the twentieth century reduced the ozone losses owing to halocarbon increases, and the N(2)O chemical destruction of O(3) is buffered by CO(2) thermal effects in the middle stratosphere (by approx. 20% for the IPCC A1B/WMO A1 scenario over the time period 1900-2100). Nonetheless, N(2)O is expected to continue to be the largest anthropogenic emission of an O(3)-destroying compound in the foreseeable future. Reductions in anthropogenic N(2)O emissions provide a larger opportunity for reduction in future O(3) depletion than any of the remaining uncontrolled halocarbon emissions. It is also shown that 1980 levels of O(3) were affected by halocarbons, N(2)O, CO(2) and CH(4), and thus may not be a good choice of a benchmark of O(3) recovery.

Experimental and theoretical study of the atmospheric chemistry and global warming potential of SO2F2.

In this work, potential atmospheric loss processes for SO2F2, a commercially used biocide (fumigant), have been studied and its global warming potential calculated. Rate coefficients for the gas-phase reactions OH + SO2F2 --> products, k1, and Cl + SO2F2 --> products, k4, were determined using a relative rate technique to be k1 < 1 x 10(-16) cm3 molecule-1 s-1 at 296 and 333 K and k4(296 K) < 5 x 10(-17) cm3 molecule(-1) s(-1). UV absorption cross sections of SO2F2 were measured at 184.9, 193, and 213.9 nm, and its photolysis quantum yield at 193 nm was determined to be <0.02. The atmospheric lifetime of SO2F2 with respect to loss by OH, Cl, and O(1D) reaction and UV photodissociation is estimated to be >300, >10000, 700, and >4700 years, respectively. The stratospheric lifetime of SO2F2 is calculated using a two-dimensional model to be 630 years. The global warming potential (GWP) for SO2F2 was calculated to be 4780 for the 100 year time horizon using infrared absorption cross sections measured in this work and a SO2F2 globally averaged atmospheric lifetime of 36 years, which is determined primarily by ocean uptake, reported by Mühle et al. (Mühle, J.; Huang, J.; Weiss, R. F.; Prinn, R. G.; Miller, B. R.; Salameh, P. K.; Harth, C. M.; Fraser, P. J.; Porter, L. W.; Greally, B. R.; O'Doherty, S.; Simonds, P. G. J. Geophys. Res., submitted for publication, 2008). Reaction channels and the possible formation of stable adducts in reactions 1 and 4 were evaluated using ab initio, CCSD(T), and density functional theory, B3P86, quantum mechanical electronic structure calculations. The most likely reaction product channels were found to be highly endothermic, consistent with the upper limits of the rate coefficients measured in this work.

The effects of hydrocortisone on systemic arterial blood pressure and urinary protein excretion in dogs.

BACKGROUND: Hypertension and proteinuria are commonly recognized in dogs with spontaneous hypercortisolism. There is, however, little information regarding the effect of exogenous glucocorticoids on blood pressure (BP) and proteinuria and whether these changes are reversible. HYPOTHESIS: Hydrocortisone administration increases systemic BP and urinary protein excretion, and these effects are reversible after hydrocortisone withdrawal. ANIMALS: Six control dogs and 6 dogs treated with hydrocortisone. METHODS: BP, urine protein : creatinine ratio (UPC), microalbuminuria (MALB), urine albumin : creatinine ratio (UAC), and urine gel electrophoresis were evaluated before, during, and after administration of hydrocortisone (8 mg/kg PO q12h for 12 weeks) or placebo. RESULTS: BP and UPC increased substantially during hydrocortisone administration from 123 mmHg (range 114-136 mmHg) and 0.17 (0.15-0.28) to a maximum of 143 mmHg (128-148 mmHg) and 0.38 (0.18-1.78), respectively, on day 28. MALB developed in 4 dogs and UAC significantly increased in all dogs during hydrocortisone administration with the maximum on day 84. Both increases in BP and proteinuria were reversible and completely resolved within 1 month after stopping hydrocortisone administration. SDS-AGE revealed the proteinuria to be primarily albuminuria with a pronounced increase during hydrocortisone treatment. Furthermore, a protein of 25-30 kDa was found in male dogs, identified by mass spectrometry to be arginine esterase, the major secretory prostatic protein. CONCLUSIONS AND CLINICAL IMPORTANCE: Long-term hydrocortisone treatment results in significant but only mild increases in systemic BP and urinary protein excretion, which are both reversible within 1 month after discontinuation of hydrocortisone.

CF3CF=CH2 and (Z)-CF3CF=CHF: temperature dependent OH rate coefficients and global warming potentials.

Rate coefficients over the temperature range 206-380 K are reported for the gas-phase reaction of OH radicals with 2,3,3,3-tetrafluoropropene (CF(3)CF=CH(2)), k(1)(T), and 1,2,3,3,3-pentafluoropropene ((Z)-CF(3)CF=CHF), k(2)(T), which are major components in proposed substitutes for HFC-134a (CF(3)CFH(2)) in mobile air-conditioning units. Rate coefficients were measured under pseudo-first-order conditions in OH using pulsed-laser photolysis to produce OH and laser-induced fluorescence to detect it. Rate coefficients were found to be independent of pressure between 25 and 600 Torr (He, N(2)). For CF(3)CF=CH(2), the rate coefficients, within the measurement uncertainty, are given by the Arrhenius expression k(1)(T)=(1.26+/-0.11) x 10(-12) exp[(-35+/-10)/T] cm(3) molecule(-1) s(-1) where k(1)(296 K)=(1.12+/-0.09) x 10(-12) cm(3) molecule(-1) s(-1). For (Z)-CF(3)CF=CHF, the rate coefficients are given by the non-Arrhenius expression k(2)(T)=(1.6+/-0.2) x 10(-18)T(2) exp[(655+/-50)/T] cm(3) molecule(-1) s(-1) where k(2)(296 K)=(1.29+/-0.06) x 10(-12) cm(3) molecule(-1) s(-1). Over the temperature range most relevant to the atmosphere, 200-300 K, the Arrhenius expression k(2)(T)=(7.30+/-0.7) x 10(-13) exp[(165+/-20)/T] cm(3) molecule(-1) s(-1) reproduces the measured rate coefficients very well and can be used in atmospheric model calculations. The quoted uncertainties in the rate coefficients are 2sigma (95% confidence interval) and include estimated systematic errors. The global warming potentials for CF(3)CF=CH(2) and (Z)-CF(3)CF=CHF were calculated to be <4.4 and <3.6, respectively, for the 100 year time horizon using infrared absorption cross sections measured in this work, and atmospheric lifetimes of 12 and 10 days that are based solely on OH reactive loss.

Rate coefficients for the reactions of OH with CF3CH2CH3 (HFC-263fb), CF3CHFCH2F (HFC-245eb), and CHF2CHFCHF2 (HFC-245ea) between 238 and 375 K.

Rate coefficients for reaction of the hydroxyl radical (OH) with three hydrofluorocarbons (HFCs) CF3CH2CH3, HFC-263fb, (k1); CF3CHFCH2F, HFC-245eb, (k2); and CHF2CHFCHF2, HFC-245ea, (k3); which are suggested as potential substitutes to chlorofluorocarbons (CFCs), were measured using pulsed laser photolysis-laser-induced fluorescence (PLP-LIF) between 235 and 375 K. The Arrhenius expressions obtained are k1(T) = (4.36 +/- 0.72) x 10(-12) exp[-(1290 +/- 40)/T] cm3 molecule(-1) s(-1); k2(T) = (1.23 +/- 0.18) x 10(-12) exp[-(1250 +/- 40)/T] cm3 molecule(-1) s(-1); k3(T) = (1.91 +/- 0.42) x 10(-12) exp[-(1375 +/- 100)/T] cm3 molecule(-1) s(-1). The quoted uncertainties are 95% confidence limits and include estimated systematic errors. The present results are discussed and compared with rate coefficients available in the literature. Our results are also compared with those calculated using structure activity relationships (SAR) for fluorinated compounds. The IR absorption cross-sections at room temperature for these compounds were measured over the range of 500 to 4000 cm-1. The global warming potentials (GWPs) of CF3CH2CH3(HFC-263fb), CF3CHFCH2F(HFC-245eb), and CHF2CHFCHF2(HFC-245ea) were calculated to be 234, 962, and 723 for a 20-year horizon; 70, 286, and 215 for a 100-year horizon; and 22, 89, and 68 for a 500-year horizon; and the atmospheric lifetimes of these compounds are 0.8, 2.5, and 2.6 years, respectively. It is concluded that these compounds are acceptable substitutes for CFCs in terms of their impact on Earth's climate.

Rate coefficients for the OH + CFH2CH2OH reaction between 238 and 355 K.

The rate coefficient for the reaction OH + CFH2CH2OH --> products (k1) between 238 and 355 K was measured using the pulsed laser photolysis-laser induced fluorescence (PLP-LIF) technique to be (5.15 +/- 0.88)x 10(-12) exp[-(330 +/- 45)/T] cm3 molecule(-1) s(-1); k1(298 K)= 1.70 x 10(-12) cm3 molecule(-1) s(-1). The quoted uncertainties are 2sigma(95% confidence level) and include estimated systematic errors. The present results are discussed in relation to the measured rate coefficients for the reaction of OH with other fluorinated alcohols and those calculated using recently reported structure additivity relationships for fluorinated compounds (K. Tokuhashi, H. Nagai, A. Takahashi, M. Kaise, S. Kondo, A. Sekiya, M. Takahashi, Y. Gotoh and A. Suga, J. Phys. Chem. A, 1999, 103, 2664-2672, ). Infrared absorption cross sections for CFH2CH2OH are reported and they are used to calculate the global warming potentials (GWP) for CFH2CH2OH of approximately 8, approximately 2, and approximately 1, respectively, for the 20, 100 and 500 year horizons. A brief discussion of the atmospheric degradation of CFH2CH2OH is provided. It is concluded that CFH2CH2OH is an acceptable substitute for CFCs in terms of its impact on Earth's climate and the composition of the atmosphere. The room temperature rate coefficient for the reaction OH + CFH2CH2OH --> products (k10) was measured to be 3.26 x 10(-12) cm3 molecule(-1) s(-1), in good agreement with recent measurements from this laboratory.

Measuring reactive nitrogen emissions from point sources using visible spectroscopy from aircraft.

Accurate measurements of nitrogen dioxide (NO2), a key trace gas in the formation and destruction of tropospheric ozone, are important in studies of urban pollution. Nitrogen dioxide column abundances were measured during the Texas Air Quality Study 2000 using visible absorption spectroscopy from an aircraft. The method allows for quantification of the integrated total number of nitrogen dioxide molecules in the polluted atmosphere and is hence a useful tool for measuring plumes of this key trace gas. Further, we show how such remote-sensing observations can be used to obtain information on the fluxes of nitrogen dioxide into the atmosphere with unique flexibility in terms of aircraft altitude, and the height and extent of mixing of the boundary layer. Observations of nitrogen dioxide plumes downwind of power plants were used to estimate the flux of nitrogen oxide emitted from several power plants in the Houston and Dallas metropolitan areas and in North Carolina. Measurements taken over the city of Houston were also employed to infer the total flux from the city as a whole.

Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor.

The objective of this work was to assess the pharmacokinetics of napsagatran, a low molecular weight thrombin inhibitor, after intravenous administration in a variety of laboratory animals, and prospectively to help design the first pharmacokinetic studies in man. Napsagatran is actively excreted into the bile and urine of various species and pronounced species-differences in its pharmacokinetics are observed. It is, therefore, an interesting compound to use in tests of the limitations of presently available inter-species scaling methods. The present data suggest that allometric exponent values which are consistent with the values expected for physiological processes and small organic molecules are not necessarily associated with successful predictions in man when active transport processes are involved in the disposition of the compounds. For example, compared with the values observed in man, the clearance (CL), non-renal clearance (CL(nr)) and the volume of distribution at steady state (Vd(ss)) were over-predicted by 3-, 7- and 2-fold, respectively, by use of allometry. Of the species tested, the cynomolgus monkey seemed to be the most useful for predicting kinetics in man when the approach based on concentration-time transformations was used. Thus, for half-life (t(1/2)), CL and Vd(ss), the observed mean values of 1.7 h, 459 mL min(-1) and 24 L kg(-1) in man were very close to the values predicted from the cynomolgus monkey (1.7 h, 652 mL min(-1) and 22 L kg(-1), respectively). The results show that there are large inter-species differences for kidney and liver excretion of napsagatran. This is probably because of the involvement of active transport processes, which compromised the kinetic extrapolation from animal to man, although a more thorough investigation of the transporters involved in the disposition of napsagatran is necessary to enable better understanding of the species differences observed.

Screening for urinary methadone by capillary electrophoretic immunoassays and confirmation by capillary electrophoresis-mass spectrometry.

This paper characterizes competitive binding, electrokinetic capillary-based immunoassays for urinary methadone using reagents which were commercialized for a fluorescence polarization immunoassay. After incubation of 25 microL urine with the reactants, a small aliquot of the mixture is applied onto a fused-silica capillary and the unbound fluorescein-labeled methadone tracer is monitored by capillary electrophoresis with on-column laser-induced fluorescence detection. Configurations in presence and absence of micelles were investigated, found to be capable of recognizing urinary methadone concentrations > or = 10 ng/mL, and shown to be suitable for rapid methadone screening of patient urines. Based upon shorter run times and a much better separation of free tracer and antibody-tracer complex, conditions without micelles are preferred. For confirmation analysis of urinary methadone and its major metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), capillary electrophoresis in a pH 4.6 ammonium acetate-acetic acid buffer was interphased to an atmospheric pressure ionization triple quadrupole mass spectrometry system. Using positive ion electrospray ionization and the tandem mass spectrometry mode with collision-induced dissociation in the collision cell, fragmentation of the two substances was determined. For confirmation via direct urine injection or application of a urinary extract, in-source fragmentation was employed and the first quadrupole was operated in the selected ion monitoring mode by switching between the masses of relevant precursor/product ion sets for methadone (m/z = 310, 265) and EDDP (m/z = 278, 249, 234). This capillary electrophoresis-mass spectrometry approach is shown to permit the confirmation of methadone and EDDP in patient urines that tested positive for methadone using electrokinetic capillary-based immunoassays, a fluorescence polarization immunoassay, and capillary electrophoresis with UV absorption detection.

Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Fleroxacin is a new broad-spectrum quinolone which can be given by the oral route. The present study was designed to assess the influence of bacteremia on the pharmacokinetics of a single oral dose of fleroxacin. Thirteen patients with proven bacteremia (one or more pairs of positive blood cultures, no hypotension) were given a single 400-mg fleroxacin dose orally on two occasions while also receiving standard antibiotic therapy. The first dose was administered 12 to 36 h after the last positive blood culture was drawn (day 1), and a second dose was administered 7 days later (day 7 +/- 2) to compare the pharmacokinetics between the acute and the convalescent phases of the disease. Following each administration of fleroxacin, serial plasma samples were collected for up to 72 h and were analyzed for unchanged drug by a reversed phase high-pressure liquid chromatography technique. There were no significant changes in the following pharmacokinetic parameters (mean standard deviation) the maximum concentration of drug in serum (6.4 +/- 1.5 versus 6.7 +/- 1.9 mg/liter), the minimum concentration of drug in serum, defined as the concentration of drug in serum at 24 h postdose (3.0 +/- 1.7 versus 2.5 +/- 1.2 mg/liter), the time to the maximum concentration of drug in serum (2.3 +/- 1.4 versus 2.0 +/- 1.2 h), and the elimination half-life (19.7 +/- 8.0 versus 17.9 +/- 6.9 h). Fleroxacin clearances were compared for each individual patient. A positive correlation (R2 = 0.787) was found between the values measured on day 1 and day 7. Oral clearance of fleroxacin (CL = CL/F, where F is bioavailability was slightly, but not significantly, reduced during the bacteremic phase (oral clearance, 43.8+/- 23.5 versus 48.5 +/- 17.5 ml/min.). When compared with previous results obtained in healthy young subjects, longer times to the maximum concentration of drug in serum and elimination half-lives and higher areas under the curve were observed. This could be due to the bacteremic state, the old age of the patients (mean, 66 years), and the low renal clearance (mean calculated creatinine clearance, 71.1 ml/min). A single oral dose of 400 mg of fleroxacin provides sufficient levels in serum to cover susceptible microorganisms for at least 24 h in bacteremic patients. Renal function appeared to be the key element that had to be taken into consideration to adapt fleroxacin dosage profiles in our patient population. Bacteremia itself appeared to amplify that phenomenon, but to a much lesser extent than renal function did.

Influence of rifampin on fleroxacin pharmacokinetics.

Staphylococcus aureus infections have been successfully treated in animal models with the combination of fleroxacin and rifampin. We studied the influence of rifampin, a potent cytochrome P-450 inducer, on the pharmacokinetics and biotransformation of fleroxacin in 14 healthy young male volunteers. Subjects were given 400 mg of fleroxacin orally once a day for 3 days to reach steady state. After a wash-out period of 2 days, the same subjects received 600 mg of rifampin orally once daily for 7 days. On days 5 to 7 of rifampin treatment, 400 mg of fleroxacin was again administered once daily. Concentrations of fleroxacin as well as its two major urinary metabolites, N-demethyl- and N-oxide-fleroxacin, in plasma and urine were determined by reverse-phase high-performance liquid chromatography. The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h. There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min). The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01). Despite being statistically significant, this 15% increase in total plasma clearance does not appear to be clinically relevant. Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min). Fleroxacin elimination was slightly increased (about 15%) through induction of metabolic clearance to N-demethyl-fleroxacin. Since fleroxacin levels remained above the MIC for 90% of the tested isolates of methicillin-susceptible S. aureus for at least 24 h, dose adjustment does not appear necessary, at least for short-term treatments.

Penetration of fleroxacin into body tissues and fluids.

Concentrations of fleroxacin in human body fluids and tissues were studied to obtain information about the efficacy of the drug at the site of infection and the ratio of fleroxacin concentrations in tissue or fluid versus those in plasma as a measure of the extent of penetration. Samples of body fluids and tissues were obtained at various intervals after oral administration, and fleroxacin concentrations were determined by high-performance liquid chromatography. After administration of the standard dose of 400 mg once daily, the maximal plasma concentrations were 5-7 mg/L at steady-state and the minimal concentrations were approximately 1 mg/L at the end of the dosing interval. In most biologic specimens, such as myometrium, fallopian tube, bile bladder wall, bone, tonsils, maxillary sinus mucosa, prostatic adenoma, sputum, inflammatory fluid, synovia, lymph, saliva, and tears, the levels of fleroxacin were similar to those in plasma. In bile, nasal secretions, seminal fluid, lung, bronchial mucosa, and ovaries, the drug concentrations were 2-3 times higher than those in plasma. Penetration of fleroxacin into fat, lens, bronchial secretions, sweat, and aqueous humor was limited, with drug levels reaching only 10-40% of the concomitant levels in plasma. The measured concentration ratios did not vary markedly with time, and the decline in drug concentrations in tissues and fluids was generally parallel to that in plasma. The breakpoint for susceptibility is 1 micrograms/mL. The susceptibility breakpoint was exceeded by the drug concentration in plasma for the entire dosing interval and was also reached or exceeded in most body tissues and fluids.

Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.

Fleroxacin was administered to seven lactating women as a single oral dose of 400 mg. Plasma, urine, and milk samples were collected for up to 48 h after administration. Drug concentrations were determined by a reversed-phase high-pressure liquid chromatography method and were used for the pharmacokinetic evaluation. At approximately 2 h after oral administration, a maximum concentration of 5.6 mg/liter was determined in plasma; the area under the plasma concentration-time curve (AUC) amounted to 70.3 mg.h/liter, and the elimination half-life in the postdistributive phase was 8 h. Total systemic clearance was 97.3 ml/min, and urinary excretion was 38% of the dose within 48 h. In addition, 8.6% of the N-demethyl metabolite and 4.4% of the N-oxide metabolite were recovered from urine. In comparison with previous results obtained with healthy male volunteers, the time to reach maximum concentrations in plasma was twice as long in the nursing women, and total clearance as well as urinary elimination were reduced by 25%. In breast milk, the mean maximum concentration was 3.5 mg/liter, which was reached 2.6 h after drug administration. The elimination half-life of fleroxacin in milk was identical to that in plasma, and the AUC reached 43.3 mg.h/liter. On the basis of the comparison of the AUC in milk versus the AUC in plasma, the proportion of fleroxacin penetration into milk was 62%. The cumulative excretion in milk amounted to only 0.219 mg within 48 h. On the basis of an average daily intake of milk of a breast-fed child of 150 ml/kg of body weight, the maximum daily ingested fleroxacin dose would not exceed 10 mg. However, quinolones are known to induce arthropathy in juvenile animals, and therefore, administration of fleroxacin to breast-feeding women cannot be allowed.

Interaction of obidoxime with sarin in aqueous solution.

The interaction of obidoxime (Toxogonin) with sarin was shown by different analytical methods. The UV spectrum of obidoxime at pH 7.4 yields two absorption maxima, lambda 1 = 284 nm and lambda 2 = 353 nm. The peak at lambda 2 = 353 nm is representative for the amount of zwitter-ionic obidoxime, i.e. the active form of obidoxime. By addition of sarin, lambda 1 shifts immediately to 278 nm and the intensity at lambda 2 decreases, thus indicating an interaction. TLC and 31P-NMR evidence shows that both mono-phosphonylated and diphosphonylated obidoximes are present. Decomposition of phosphonylated obidoxime in MOPS (3-[N-morpholino] propanesulfonic acid) buffered D2O at pH 7.4 occurs with t1/2 = 13.3 min at 24 degrees C. Decomposition of di-phosphonylated obidoxime is faster. It is suggested that decomposition of di-phosphonylated obidoxime occurs through the mono-phosphonylated form. Formation and decomposition of mono- and di-phosphonylated obidoxime is pH dependent. We conclude that obidoxime exerts a detoxifying effect by capturing free sarin molecules and thus increasing its polarity. Thereby the transition of sarin through the blood-brain barrier is restricted and its renal elimination facilitated.

Penetration of fleroxacin into human and animal tissues.

Fleroxacin concentrations in human and rat tissues were determined by HPLC following extraction with dichloromethane:isopropanol. This method yielded a high recovery of more than 85%. In the investigated tissues the fleroxacin levels were equal to or higher than those concomitantly measured in plasma. The concentration ratios 'tissue/plasma' were 1.6-2.7 for lung, 1.9-2.1 for muscle, 1.1-1.9 for gynaecological tissues and 1.2 for bone. Only in the case of fat and lens/eye lower ratios of 0.05-0.5 were found. The actual measured fleroxacin concentrations in most tissues and in plasma were high. Following oral administration of the recommended therapeutic dose of 400 mg, once daily, peak concentrations of 5-6 mg/l were reached in human plasma at steady state. Even 24 h after drug intake the fleroxacin level was still approximately 1 mg/l and thus in the range of the MIC90 values of susceptible bacteria causative for many types of tissue infections.